O	0	7	Epstein	Epstein	NNP	B-NP
O	7	8	-	-	HYPH	I-NP
O	8	12	Barr	Barr	NNP	I-NP
O	13	18	virus	virus	NN	I-NP
O	18	19	-	-	HYPH	O
O	19	29	associated	associate	VBN	B-VP
B-Cancer	30	38	nonsmall	nonsmall	JJ	B-NP
I-Cancer	39	43	cell	cell	NN	I-NP
I-Cancer	44	48	lung	lung	NN	I-NP
I-Cancer	49	58	carcinoma	carcinoma	NN	I-NP
O	58	59	:	:	:	O
O	60	76	undifferentiated	undifferentiated	JJ	B-NP
B-Cancer	77	78	"	"	``	I-NP
I-Cancer	78	95	lymphoepithelioma	lymphoepithelioma	NN	I-NP
I-Cancer	95	96	-	-	HYPH	I-NP
I-Cancer	96	100	like	like	JJ	I-NP
I-Cancer	100	101	"	"	''	I-NP
I-Cancer	102	111	carcinoma	carcinoma	NN	I-NP
O	112	114	as	as	IN	B-PP
O	115	116	a	a	DT	B-NP
O	117	125	distinct	distinct	JJ	I-NP
O	126	132	entity	entity	NN	I-NP
O	133	137	with	with	IN	B-PP
O	138	144	better	good	JJR	B-NP
O	145	154	prognosis	prognosis	NN	I-NP
O	154	155	.	.	.	O

O	156	166	BACKGROUND	BACKGROUND	NN	B-NP
O	166	167	:	:	:	O

O	168	175	Epstein	Epstein	NNP	B-NP
O	175	176	-	-	HYPH	I-NP
O	176	180	Barr	Barr	NNP	I-NP
O	181	186	virus	virus	NN	I-NP
O	187	188	(	(	(	O
O	188	191	EBV	EBV	NN	B-NP
O	191	192	)	)	)	O
O	193	202	infection	infection	NN	B-NP
O	203	205	in	in	IN	B-PP
B-Cancer	206	214	nonsmall	nonsmall	JJ	B-NP
I-Cancer	215	219	cell	cell	NN	I-NP
I-Cancer	220	224	lung	lung	NN	I-NP
I-Cancer	225	234	carcinoma	carcinoma	NN	I-NP
O	235	236	(	(	(	O
B-Cancer	236	241	NSCLC	NSCLC	NN	B-NP
O	241	242	)	)	)	O
O	243	246	has	have	VBZ	B-VP
O	247	251	been	be	VBN	I-VP
O	252	264	demonstrated	demonstrate	VBN	I-VP
O	265	267	in	in	IN	B-PP
O	268	272	some	some	DT	B-NP
O	273	279	ethnic	ethnic	JJ	I-NP
O	280	286	groups	group	NNS	I-NP
O	286	287	.	.	.	O

O	288	291	The	The	DT	B-NP
O	292	304	pathobiology	pathobiology	NN	I-NP
O	305	308	and	and	CC	O
O	309	312	the	the	DT	B-NP
O	313	317	role	role	NN	I-NP
O	318	320	of	of	IN	B-PP
O	321	324	EBV	EBV	NN	B-NP
O	325	328	and	and	CC	O
O	329	340	oncoprotein	oncoprotein	NN	B-NP
O	341	351	expression	expression	NN	I-NP
O	352	354	in	in	IN	B-PP
O	355	360	these	these	DT	B-NP
B-Cancer	361	367	tumors	tumor	NNS	I-NP
O	368	372	have	have	VBP	B-VP
O	373	376	not	not	RB	I-VP
O	377	381	been	be	VBN	I-VP
O	382	389	studied	study	VBN	I-VP
O	390	401	extensively	extensively	RB	B-ADVP
O	401	402	.	.	.	O

O	403	405	In	In	IN	B-PP
O	406	410	this	this	DT	B-NP
O	411	416	study	study	NN	I-NP
O	416	417	,	,	,	O
O	418	421	the	the	DT	B-NP
O	422	429	authors	author	NNS	I-NP
O	430	442	investigated	investigate	VBD	B-VP
O	443	446	EBV	EBV	NN	B-NP
O	446	447	-	-	HYPH	O
O	447	454	encoded	encode	VBN	B-NP
O	455	458	RNA	RNA	NN	I-NP
O	458	459	-	-	HYPH	B-NP
O	459	460	1	1	CD	I-NP
O	461	462	(	(	(	O
O	462	467	EBER1	EBER1	NN	B-NP
O	467	468	)	)	)	O
O	469	480	transcripts	transcript	NNS	B-NP
O	481	483	by	by	IN	B-PP
O	484	486	in	in	FW	B-NP
O	487	491	situ	situ	FW	I-NP
O	492	505	hybridization	hybridization	NN	I-NP
O	506	509	and	and	CC	O
O	510	513	the	the	DT	B-NP
O	514	524	expression	expression	NN	I-NP
O	525	527	of	of	IN	B-PP
O	528	534	latent	latent	JJ	B-NP
O	535	543	membrane	membrane	NN	I-NP
O	544	551	protein	protein	NN	I-NP
O	551	552	-	-	HYPH	B-NP
O	552	553	1	1	CD	I-NP
O	554	555	(	(	(	O
O	555	558	LMP	LMP	NN	B-NP
O	558	559	-	-	HYPH	B-NP
O	559	560	1	1	CD	I-NP
O	560	561	)	)	)	O
O	562	565	and	and	CC	O
O	566	569	bcl	bcl	NN	B-NP
O	569	570	-	-	HYPH	O
O	570	571	2	2	CD	B-NP
O	572	579	protein	protein	NN	I-NP
O	580	582	by	by	IN	B-PP
O	583	603	immunohistochemistry	immunohistochemistry	NN	B-NP
O	604	606	in	in	IN	B-PP
B-Cancer	607	612	NSCLC	NSCLC	NN	B-NP
O	613	621	patients	patient	NNS	I-NP
O	622	626	from	from	IN	B-PP
O	627	633	Taiwan	Taiwan	NNP	B-NP
O	633	634	,	,	,	O
O	635	640	where	where	WRB	B-ADVP
B-Cancer	641	655	nasopharyngeal	nasopharyngeal	JJ	B-NP
I-Cancer	656	665	carcinoma	carcinoma	NN	I-NP
O	666	668	is	be	VBZ	B-VP
O	669	676	endemic	endemic	JJ	B-ADJP
O	676	677	.	.	.	O

O	678	685	METHODS	METHODS	NNS	B-NP
O	685	686	:	:	:	O

O	687	688	A	A	DT	B-NP
O	689	694	total	total	NN	I-NP
O	695	697	of	of	IN	B-PP
O	698	701	127	127	CD	B-NP
O	702	707	cases	case	NNS	I-NP
O	708	710	of	of	IN	B-PP
B-Cancer	711	716	NSCLC	NSCLC	NN	B-NP
O	717	718	(	(	(	O
O	718	720	43	43	CD	B-NP
O	721	726	cases	case	NNS	I-NP
O	727	729	of	of	IN	B-PP
B-Cancer	730	738	squamous	squamous	JJ	B-NP
I-Cancer	739	743	cell	cell	NN	I-NP
I-Cancer	744	753	carcinoma	carcinoma	NN	I-NP
O	754	755	[	[	(	O
B-Cancer	755	758	SCC	SCC	NN	B-NP
O	758	759	]	]	)	O
O	759	760	,	,	,	O
O	761	763	67	67	CD	B-NP
O	764	769	cases	case	NNS	I-NP
O	770	772	of	of	IN	B-PP
B-Cancer	773	787	adenocarcinoma	adenocarcinoma	NN	B-NP
O	788	789	[	[	(	O
B-Cancer	789	791	AD	AD	NN	B-NP
O	791	792	]	]	)	O
O	792	793	,	,	,	O
O	794	796	12	12	CD	B-NP
O	797	802	cases	case	NNS	I-NP
O	803	805	of	of	IN	B-PP
B-Cancer	806	811	large	large	JJ	B-NP
I-Cancer	812	816	cell	cell	NN	I-NP
I-Cancer	817	826	carcinoma	carcinoma	NN	I-NP
O	827	828	[	[	(	O
B-Cancer	828	831	LCC	LCC	NN	B-NP
O	831	832	]	]	)	O
O	832	833	,	,	,	O
O	834	837	and	and	CC	O
O	838	839	5	5	CD	B-NP
O	840	845	cases	case	NNS	I-NP
O	846	848	of	of	IN	B-PP
B-Cancer	849	866	lymphoepithelioma	lymphoepithelioma	NN	B-NP
I-Cancer	866	867	-	-	HYPH	B-NP
I-Cancer	867	871	like	like	JJ	I-NP
I-Cancer	872	881	carcinoma	carcinoma	NN	I-NP
O	882	883	[	[	(	O
B-Cancer	883	885	LE	LE	NN	B-NP
O	885	886	]	]	)	O
O	886	887	)	)	)	O
O	888	892	were	be	VBD	B-VP
O	893	901	included	include	VBN	I-VP
O	901	902	.	.	.	O

O	903	904	A	A	DT	B-NP
O	905	914	sensitive	sensitive	JJ	I-NP
O	915	925	polymerase	polymerase	NN	I-NP
O	926	931	chain	chain	NN	I-NP
O	932	940	reaction	reaction	NN	I-NP
O	940	941	-	-	HYPH	O
O	941	948	derived	derive	VBN	B-VP
O	948	949	,	,	,	O
O	950	961	digoxigenin	digoxigenin	NN	B-NP
O	961	962	-	-	HYPH	B-VP
O	962	969	labeled	label	VBN	B-NP
O	970	973	DNA	DNA	NN	I-NP
O	974	979	probe	probe	NN	I-NP
O	980	983	for	for	IN	B-PP
O	984	986	in	in	FW	B-NP
O	987	991	situ	situ	FW	I-NP
O	992	1001	detection	detection	NN	I-NP
O	1002	1004	of	of	IN	B-PP
O	1005	1010	EBER1	EBER1	NN	B-NP
O	1011	1022	transcripts	transcript	NNS	I-NP
O	1023	1026	was	be	VBD	B-VP
O	1027	1036	performed	perform	VBN	I-VP
O	1037	1040	for	for	IN	B-PP
O	1041	1044	the	the	DT	B-NP
O	1045	1054	detection	detection	NN	I-NP
O	1055	1057	of	of	IN	B-PP
O	1058	1061	EBV	EBV	NN	B-NP
O	1061	1062	.	.	.	O

O	1063	1083	Immunohistochemistry	Immunohistochemistry	NN	B-NP
O	1084	1089	using	use	VBG	B-VP
O	1090	1093	the	the	DT	B-NP
O	1094	1100	avidin	avidin	NN	I-NP
O	1100	1101	-	-	HYPH	B-NP
O	1101	1107	biotin	biotin	NN	I-NP
O	1107	1108	-	-	HYPH	I-NP
O	1108	1124	immunoperoxidase	immunoperoxidase	NN	I-NP
O	1125	1131	method	method	NN	I-NP
O	1132	1135	was	be	VBD	B-VP
O	1136	1140	also	also	RB	I-VP
O	1141	1150	performed	perform	VBN	I-VP
O	1151	1153	to	to	TO	I-VP
O	1154	1162	evaluate	evaluate	VB	I-VP
O	1163	1166	the	the	DT	B-NP
O	1167	1177	expression	expression	NN	I-NP
O	1178	1180	of	of	IN	B-PP
O	1181	1184	bcl	bcl	NN	B-NP
O	1184	1185	-	-	HYPH	B-NP
O	1185	1186	2	2	CD	I-NP
O	1187	1190	and	and	CC	O
O	1191	1194	LMP	LMP	NN	B-NP
O	1194	1195	-	-	HYPH	B-NP
O	1195	1196	1	1	CD	I-NP
O	1196	1197	.	.	.	O

O	1198	1205	RESULTS	RESULTS	NNS	B-NP
O	1205	1206	:	:	:	O

O	1207	1212	EBER1	EBER1	NN	B-NP
O	1213	1216	was	be	VBD	B-VP
O	1217	1225	detected	detect	VBN	I-VP
O	1226	1228	in	in	IN	B-PP
O	1229	1231	11	11	CD	B-NP
O	1232	1234	of	of	IN	B-PP
O	1235	1238	the	the	DT	B-NP
O	1239	1242	127	127	CD	I-NP
B-Cancer	1243	1248	NSCLC	NSCLC	NN	I-NP
O	1249	1254	cases	case	NNS	I-NP
O	1255	1256	(	(	(	O
O	1256	1257	8	8	CD	B-NP
O	1257	1258	.	.	.	O
O	1258	1259	7	7	CD	B-NP
O	1259	1260	%	%	NN	I-NP
O	1260	1261	;	;	:	O
O	1262	1263	6	6	CD	B-NP
B-Cancer	1264	1267	SCC	SCC	NN	I-NP
O	1268	1273	cases	case	NNS	I-NP
O	1274	1277	and	and	CC	O
O	1278	1279	5	5	CD	B-NP
B-Cancer	1280	1282	LE	LE	NN	I-NP
O	1283	1288	cases	case	NNS	I-NP
O	1288	1289	)	)	)	O
O	1289	1290	.	.	.	O

O	1291	1294	All	All	DT	B-NP
O	1295	1296	5	5	CD	I-NP
B-Cancer	1297	1299	LE	LE	NN	I-NP
O	1300	1305	cases	case	NNS	I-NP
O	1306	1310	were	be	VBD	B-VP
O	1311	1314	EBV	EBV	NN	B-NP
O	1314	1315	-	-	HYPH	B-ADJP
O	1315	1323	positive	positive	JJ	I-ADJP
O	1323	1324	,	,	,	O
O	1325	1332	whereas	whereas	IN	O
O	1333	1337	only	only	RB	B-NP
O	1338	1339	6	6	CD	I-NP
O	1340	1342	of	of	IN	B-PP
O	1343	1346	the	the	DT	B-NP
O	1347	1349	43	43	CD	I-NP
B-Cancer	1350	1353	SCC	SCC	NN	I-NP
O	1354	1359	cases	case	NNS	I-NP
O	1360	1361	(	(	(	O
O	1361	1363	14	14	CD	B-NP
O	1363	1364	%	%	NN	I-NP
O	1364	1365	)	)	)	O
O	1365	1366	,	,	,	O
O	1367	1368	0	0	CD	B-NP
O	1369	1371	of	of	IN	B-PP
O	1372	1374	67	67	CD	B-NP
B-Cancer	1375	1377	AD	AD	NN	I-NP
O	1378	1383	cases	case	NNS	I-NP
O	1383	1384	,	,	,	O
O	1385	1388	and	and	CC	O
O	1389	1391	12	12	CD	B-NP
B-Cancer	1392	1395	LCC	LCC	NN	I-NP
O	1396	1401	cases	case	NNS	I-NP
O	1402	1406	were	be	VBD	B-VP
O	1407	1410	EBV	EBV	NN	B-NP
O	1410	1411	-	-	HYPH	O
O	1411	1419	positive	positive	JJ	B-ADJP
O	1420	1421	(	(	(	O
O	1421	1422	P	P	NN	B-NP
O	1423	1424	<	<	SYM	B-ADJP
O	1425	1426	0	0	CD	B-NP
O	1426	1427	.	.	.	I-NP
O	1427	1429	05	05	CD	I-NP
O	1429	1430	)	)	)	O
O	1430	1431	.	.	.	O

O	1432	1435	All	All	DT	B-NP
O	1436	1440	five	five	CD	I-NP
B-Cancer	1441	1443	LE	LE	NN	I-NP
O	1444	1449	cases	case	NNS	I-NP
O	1450	1456	showed	show	VBD	B-VP
O	1457	1464	diffuse	diffuse	JJ	B-NP
O	1464	1465	,	,	,	I-NP
O	1466	1472	strong	strong	JJ	I-NP
O	1472	1473	,	,	,	I-NP
O	1474	1482	positive	positive	JJ	I-NP
O	1483	1491	staining	staining	NN	I-NP
O	1492	1494	of	of	IN	B-PP
B-Cell	1495	1500	tumor	tumor	NN	B-NP
I-Cell	1501	1506	cells	cell	NNS	I-NP
O	1506	1507	;	;	:	O
O	1508	1512	five	five	CD	B-NP
O	1513	1515	of	of	IN	B-PP
O	1516	1519	the	the	DT	B-NP
O	1520	1523	six	six	CD	I-NP
B-Cancer	1524	1527	SCC	SCC	NN	I-NP
O	1528	1533	cases	case	NNS	I-NP
O	1534	1540	showed	show	VBD	B-VP
O	1541	1548	diffuse	diffuse	JJ	B-NP
O	1549	1552	but	but	CC	I-NP
O	1553	1557	weak	weak	JJ	I-NP
O	1558	1566	staining	staining	NN	I-NP
O	1566	1567	.	.	.	O

O	1568	1573	Among	Among	IN	B-PP
O	1574	1577	the	the	DT	B-NP
B-Cell	1578	1586	nontumor	nontumor	JJ	I-NP
I-Cell	1587	1597	epithelial	epithelial	JJ	I-NP
I-Cell	1598	1603	cells	cell	NNS	I-NP
O	1603	1604	,	,	,	O
O	1605	1610	there	there	EX	B-NP
O	1611	1614	was	be	VBD	B-VP
O	1615	1617	no	no	DT	B-NP
O	1618	1623	EBER1	EBER1	NN	I-NP
O	1624	1632	staining	staining	NN	I-NP
O	1633	1635	of	of	IN	B-PP
O	1636	1639	any	any	DT	B-NP
O	1640	1642	of	of	IN	B-PP
O	1643	1646	the	the	DT	B-NP
O	1647	1649	11	11	CD	I-NP
O	1650	1655	EBER1	EBER1	NN	I-NP
O	1655	1656	-	-	HYPH	B-NP
O	1656	1664	positive	positive	JJ	I-NP
O	1665	1670	cases	case	NNS	I-NP
O	1670	1671	.	.	.	O

O	1672	1675	The	The	DT	B-NP
O	1676	1680	mean	mean	JJ	I-NP
O	1681	1684	age	age	NN	I-NP
O	1685	1687	of	of	IN	B-PP
O	1688	1691	the	the	DT	B-NP
B-Cancer	1692	1694	LE	LE	NN	I-NP
O	1695	1703	patients	patient	NNS	I-NP
O	1704	1707	was	be	VBD	B-VP
O	1708	1710	10	10	CD	B-NP
O	1711	1716	years	year	NNS	I-NP
O	1717	1724	younger	young	JJR	B-ADJP
O	1725	1729	than	than	IN	B-PP
O	1730	1734	that	that	DT	B-NP
O	1735	1737	of	of	IN	B-PP
O	1738	1741	the	the	DT	B-NP
O	1742	1750	patients	patient	NNS	I-NP
O	1751	1755	with	with	IN	B-PP
O	1756	1761	other	other	JJ	B-NP
O	1762	1774	histological	histological	JJ	I-NP
O	1775	1780	types	type	NNS	I-NP
O	1780	1781	.	.	.	O

O	1782	1785	All	All	DT	B-NP
O	1786	1787	5	5	CD	I-NP
B-Cancer	1788	1790	LE	LE	NN	I-NP
O	1791	1799	patients	patient	NNS	I-NP
O	1800	1804	were	be	VBD	B-VP
O	1805	1815	nonsmokers	nonsmoker	NNS	B-NP
O	1815	1816	,	,	,	O
O	1817	1824	whereas	whereas	IN	O
O	1825	1826	3	3	CD	B-NP
O	1827	1829	of	of	IN	B-PP
O	1830	1833	the	the	DT	B-NP
O	1834	1835	6	6	CD	I-NP
O	1836	1844	patients	patient	NNS	I-NP
O	1845	1849	with	with	IN	B-PP
O	1850	1855	EBER1	EBER1	NN	B-NP
O	1855	1856	-	-	HYPH	B-NP
O	1856	1864	positive	positive	JJ	I-NP
B-Cancer	1865	1868	SCC	SCC	NN	I-NP
O	1869	1870	(	(	(	O
O	1870	1872	50	50	CD	B-NP
O	1872	1873	%	%	NN	I-NP
O	1873	1874	)	)	)	O
O	1875	1879	were	be	VBD	B-VP
O	1880	1887	smokers	smoker	NNS	B-NP
O	1887	1888	.	.	.	O

O	1889	1894	EBER1	EBER1	NN	B-NP
O	1895	1905	expression	expression	NN	I-NP
O	1906	1909	did	do	VBD	B-VP
O	1910	1913	not	not	RB	I-VP
O	1914	1923	correlate	correlate	VB	I-VP
O	1924	1928	with	with	IN	B-PP
O	1929	1932	the	the	DT	B-NP
O	1933	1934	2	2	CD	I-NP
O	1934	1935	-	-	HYPH	I-NP
O	1935	1939	year	year	NN	I-NP
O	1940	1948	survival	survival	NN	I-NP
O	1949	1953	rate	rate	NN	I-NP
O	1954	1956	of	of	IN	B-PP
O	1957	1964	overall	overall	JJ	B-NP
O	1965	1970	cases	case	NNS	I-NP
O	1970	1971	,	,	,	O
O	1972	1975	but	but	CC	O
O	1976	1979	all	all	DT	B-NP
O	1980	1981	5	5	CD	I-NP
B-Cancer	1982	1984	LE	LE	NN	I-NP
O	1985	1993	patients	patient	NNS	I-NP
O	1994	1998	were	be	VBD	B-VP
O	1999	2004	alive	alive	JJ	B-ADJP
O	2005	2012	without	without	IN	B-PP
O	2013	2021	clinical	clinical	JJ	B-NP
O	2022	2030	evidence	evidence	NN	I-NP
O	2031	2033	of	of	IN	B-PP
O	2034	2041	disease	disease	NN	B-NP
O	2042	2044	at	at	IN	B-PP
O	2045	2049	last	last	JJ	B-NP
O	2050	2056	follow	follow	VB	I-NP
O	2056	2057	-	-	HYPH	B-ADJP
O	2057	2059	up	up	RP	B-PRT
O	2059	2060	.	.	.	O

O	2061	2067	Gender	Gender	NN	B-NP
O	2067	2068	,	,	,	O
B-Multi-tissue_structure	2069	2074	lymph	lymph	NN	B-NP
I-Multi-tissue_structure	2075	2079	node	node	NN	I-NP
O	2080	2082	or	or	CC	O
O	2083	2090	distant	distant	JJ	B-NP
O	2091	2101	metastasis	metastasis	NN	I-NP
O	2101	2102	,	,	,	O
O	2103	2106	and	and	CC	O
O	2107	2115	clinical	clinical	JJ	B-NP
O	2116	2121	stage	stage	NN	I-NP
O	2122	2126	were	be	VBD	B-VP
O	2127	2130	not	not	RB	I-VP
O	2131	2136	found	find	VBN	I-VP
O	2137	2139	to	to	TO	I-VP
O	2140	2144	have	have	VB	I-VP
O	2145	2148	any	any	DT	B-NP
O	2149	2160	correlation	correlation	NN	I-NP
O	2161	2165	with	with	IN	B-PP
O	2166	2171	EBER1	EBER1	NN	B-NP
O	2172	2182	expression	expression	NN	I-NP
O	2183	2184	(	(	(	O
O	2184	2185	P	P	NN	B-NP
O	2186	2187	>	>	SYM	B-ADJP
O	2188	2189	0	0	CD	B-NP
O	2189	2190	.	.	.	I-NP
O	2190	2192	05	05	CD	I-NP
O	2192	2193	)	)	)	O
O	2193	2194	.	.	.	O

O	2195	2198	All	All	DT	B-NP
B-Cancer	2199	2201	LE	LE	NN	I-NP
O	2202	2207	cases	case	NNS	I-NP
O	2208	2211	had	have	VBD	B-VP
O	2212	2215	bcl	bcl	NN	B-NP
O	2215	2216	-	-	HYPH	B-NP
O	2216	2217	2	2	CD	I-NP
O	2218	2229	oncoprotein	oncoprotein	NN	I-NP
O	2230	2240	expression	expression	NN	I-NP
O	2241	2242	(	(	(	O
O	2242	2245	100	100	CD	B-NP
O	2245	2246	%	%	NN	I-NP
O	2246	2247	)	)	)	O
O	2247	2248	.	.	.	O

O	2249	2253	This	This	DT	B-NP
O	2254	2263	frequency	frequency	NN	I-NP
O	2264	2267	was	be	VBD	B-VP
O	2268	2281	significantly	significantly	RB	B-ADJP
O	2282	2291	different	different	JJ	I-ADJP
O	2292	2296	from	from	IN	B-PP
O	2297	2302	other	other	JJ	B-NP
O	2303	2313	histologic	histologic	JJ	I-NP
O	2314	2319	types	type	NNS	I-NP
O	2320	2321	(	(	(	O
O	2321	2322	P	P	NN	B-NP
O	2323	2324	<	<	SYM	B-ADJP
O	2325	2326	0	0	CD	B-NP
O	2326	2327	.	.	.	I-NP
O	2327	2329	05	05	CD	I-NP
O	2329	2330	)	)	)	O
O	2330	2331	.	.	.	O

O	2332	2335	The	The	DT	B-NP
O	2336	2339	LMP	LMP	NN	I-NP
O	2339	2340	-	-	HYPH	B-NP
O	2340	2341	1	1	CD	I-NP
O	2342	2351	detection	detection	NN	I-NP
O	2352	2356	rate	rate	NN	I-NP
O	2357	2360	was	be	VBD	B-VP
O	2361	2364	low	low	JJ	B-ADJP
O	2365	2368	and	and	CC	O
O	2369	2381	demonstrated	demonstrate	VBD	B-VP
O	2382	2384	no	no	DT	B-NP
O	2385	2396	correlation	correlation	NN	I-NP
O	2397	2401	with	with	IN	B-PP
O	2402	2405	bcl	bcl	NN	B-NP
O	2405	2406	-	-	HYPH	O
O	2406	2407	2	2	CD	B-NP
O	2408	2418	expression	expression	NN	I-NP
O	2418	2419	.	.	.	O

O	2420	2431	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	2431	2432	:	:	:	O

O	2433	2435	In	In	IN	B-PP
O	2436	2440	this	this	DT	B-NP
O	2441	2446	study	study	NN	I-NP
O	2446	2447	,	,	,	O
O	2448	2451	the	the	DT	B-NP
O	2452	2459	authors	author	NNS	I-NP
O	2460	2465	found	find	VBD	B-VP
O	2466	2470	that	that	IN	B-SBAR
O	2471	2474	the	the	DT	B-NP
B-Cancer	2475	2482	primary	primary	JJ	I-NP
I-Cancer	2483	2485	LE	LE	NN	I-NP
O	2486	2488	of	of	IN	B-PP
O	2489	2492	the	the	DT	B-NP
B-Organ	2493	2497	lung	lung	NN	I-NP
O	2498	2500	is	be	VBZ	B-VP
O	2501	2511	associated	associate	VBN	I-VP
O	2512	2516	with	with	IN	B-PP
O	2517	2522	young	young	JJ	B-NP
O	2523	2526	age	age	NN	I-NP
O	2526	2527	,	,	,	O
O	2528	2529	a	a	DT	B-NP
O	2530	2537	history	history	NN	I-NP
O	2538	2540	of	of	IN	B-PP
O	2541	2544	not	not	RB	B-NP
O	2545	2552	smoking	smoking	NN	I-NP
O	2552	2553	,	,	,	O
O	2554	2558	high	high	JJ	B-NP
O	2559	2562	bcl	bcl	NN	I-NP
O	2562	2563	-	-	HYPH	B-NP
O	2563	2564	2	2	CD	I-NP
O	2565	2581	immunoreactivity	immunoreactivity	NN	I-NP
O	2581	2582	,	,	,	O
O	2583	2586	and	and	CC	O
O	2587	2593	better	good	JJR	B-NP
O	2594	2602	survival	survival	NN	I-NP
O	2603	2607	rate	rate	NN	I-NP
O	2607	2608	.	.	.	O

O	2609	2614	These	These	DT	B-NP
O	2615	2630	characteristics	characteristic	NNS	I-NP
O	2631	2642	demonstrate	demonstrate	VBP	B-VP
O	2643	2647	that	that	IN	B-SBAR
O	2648	2651	EBV	EBV	NN	B-NP
O	2651	2652	-	-	HYPH	B-VP
O	2652	2662	associated	associate	VBN	B-NP
B-Cancer	2663	2665	LE	LE	NN	I-NP
O	2666	2668	of	of	IN	B-PP
O	2669	2672	the	the	DT	B-NP
B-Organ	2673	2677	lung	lung	NN	I-NP
O	2678	2680	is	be	VBZ	B-VP
O	2681	2682	a	a	DT	B-NP
O	2683	2689	unique	unique	JJ	I-NP
O	2690	2696	entity	entity	NN	I-NP
O	2696	2697	.	.	.	O

O	2698	2701	The	The	DT	B-NP
O	2702	2710	findings	finding	NNS	I-NP
O	2711	2713	of	of	IN	B-PP
O	2714	2717	the	the	DT	B-NP
O	2718	2725	current	current	JJ	I-NP
O	2726	2731	study	study	NN	I-NP
O	2732	2739	suggest	suggest	VBP	B-VP
O	2740	2744	that	that	IN	B-SBAR
O	2745	2748	EBV	EBV	NN	B-NP
O	2749	2758	infection	infection	NN	I-NP
O	2759	2762	may	may	MD	B-VP
O	2763	2767	play	play	VB	I-VP
O	2768	2769	a	a	DT	B-NP
O	2770	2779	different	different	JJ	I-NP
O	2780	2784	role	role	NN	I-NP
O	2785	2787	in	in	IN	B-PP
O	2788	2791	the	the	DT	B-NP
O	2792	2805	tumorigenesis	tumorigenesis	NN	I-NP
O	2806	2808	of	of	IN	B-PP
B-Cancer	2809	2816	primary	primary	JJ	B-NP
I-Cancer	2817	2819	LE	LE	NN	I-NP
O	2820	2822	of	of	IN	B-PP
O	2823	2826	the	the	DT	B-NP
B-Organ	2827	2831	lung	lung	NN	I-NP
O	2832	2836	than	than	IN	B-SBAR
O	2837	2839	it	it	PRP	B-NP
O	2840	2844	does	do	VBZ	B-VP
O	2845	2847	in	in	IN	B-PP
O	2848	2853	other	other	JJ	B-NP
B-Cancer	2854	2859	EBER1	EBER1	NN	I-NP
I-Cancer	2859	2860	-	-	HYPH	B-NP
I-Cancer	2860	2868	positive	positive	JJ	I-NP
I-Cancer	2869	2875	NSCLCs	NSCLC	NNS	I-NP
O	2875	2876	.	.	.	O

